archive-ie.com » IE » N » NCPE.IE

Total: 381

Choose link from "Titles, links and description words view":

Or switch to "Titles and links view".
  • News | National Centre for Pharmacoeconomics - Part 4
    after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated Eltrombopag Revolade February 14 2014 Eltrombopag Revolade is indicated in adult patients with chronic hepatitis C virus HCV infection for the treatment of thrombocytopenia where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon based therapy Rapid Review Commenced Completed Outcome 10 01 2014 13 02 2014 Full Pharmacoeconomic Evaluation not Recommended Aflibercept Zaltrap February 12 2014 The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving Vismodegib Erivedge January 22 2014 The NCPE does not recommend reimbursement of vismodegib Levodopa 20mg ml carbidopa monohydrate 5mg intestinal gel Duodopa December 31 2013 The NCPE do not recommend Duodopa at the current price Dapagliflozin Forxiga December 31 2013 The NCPE do not recommend reimbursement of dapagliflozin Abatacept Orencia November 12 2013 The NCPE do not recommend reimbursement of Subcutaneous Abatacept Orencia at the submitted price Pregabalin Lyrica for the treatment of neuropathic pain October 25 2013 Pregabalin is currently reimbursed The NCPE consider that it may be cost effective under certain assumptions Pertuzumab Perjeta August 28 2013 The NCPE believes that

    Original URL path: http://www.ncpe.ie/news/page/4/ (2015-10-30)
    Open archived version from archive

  • News | National Centre for Pharmacoeconomics - Part 5
    valvular atrial fibrillation Omega 3 acid ethyl esters Omacor April 22 2013 The NCPE believe that Omacor is not a cost effective adjuvant treatment for patients post myocardial infarction in the Irish Healthcare Setting The cost effectiveness of Omacor for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated Pirfenidone Esbriet March 20 2013 The NCPE believe that at the submitted price pirfenidone is not cost effective for the treatment of patients with mild to moderate Idiopathic Pulmonary Fibrosis Fidaxomicin Dificlir February 5 2013 Fidaxomicin Dificlir may be considered a cost effective use of resources It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines due to be completed in February 2013 www hpsc ie Ivacaftor Kalydeco February 1 2013 The NCPE recommendation on ivacaftor Kalydeco led to follow up discussions between the HSE CPU and the company Vertex Pharmaceuticals resulting in a positive recommendation on the provision of the drug for Irish CF patients whilst at the same time significantly reducing the budget impact of the drug Bendamustine Levact December 13 2012 The NCPE recommends reimbursement of bendamustine Levact for patients unable to tolerate fludarabine clyclophosphamide Eribulin Halaven

    Original URL path: http://www.ncpe.ie/news/page/5/ (2015-10-30)
    Open archived version from archive

  • News | National Centre for Pharmacoeconomics - Part 6
    Following a price revision we now consider rivaroxaban a cost effective therapy for this indication Abiraterone Acetate Zytiga for mCRPC May 22 2012 The NCPE believe that at the submitted price Abiraterone Acetate Zytiga is not cost effective for the treatment of patients with metastatic castration resistant prostate cancer mCRPC Dexamethasone Intravitreal Implant Ozurdex March 16 2012 We believe that at the submitted price Ozurdex cannot be considered cost effective therapy for the treatment of macular oedema following retinal vein occlusion Cabazitaxel Jevtana March 13 2012 The NCPE believe that at the submitted price cabazitaxel is not cost effective for the treatment of patients with mHRPC previously treated with a docetaxel containing treatment regimen Rivaroxaban Xarelto for the Treatment of Deep Vein Thrombosis February 24 2012 Full Pharmacoeconomic Evaluation Recommended Pneumococcal Vaccination February 3 2012 Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland PCV13 is the most cost effective option if the analysis is based on a serotype distribution reflecting 2011 data download document Telaprevir Incivo January 19 2012 We consider telaprevir Incivo a highly cost effective therapy when added to peginterferon ribavirin for the treatment of patients infected with genotype 1 hepatitis C virus in

    Original URL path: http://www.ncpe.ie/news/page/6/ (2015-10-30)
    Open archived version from archive

  • News | National Centre for Pharmacoeconomics - Part 7
    Ticagrelor Brilique a cost effective therapy for the prevention of atherothrombotic events in adult patients with ACS including patients managed medically and those managed with PCI or CABG Oncotype DX October 3 2011 Cost effectiveness of Oncotype DX to target chemotherapy use in lymph node negative oestrogen receptor positive early stage breast cancer in Ireland Fingolimod Gilenya September 22 2011 Following a price revision we now consider Fingolimod Gilenya a cost effective therapy for the treatment of relapsing remitting multiple sclerosis patients in the Irish healthcare setting Ipilimumab Yervoy September 6 2011 We cannot recommend reimbursement of Ipilimumab at the submitted price Dabigatran etexilate Pradaxa for the prevention of stroke and systematic embolisom in atrial fibrillation August 9 2011 Reimbursement not Recommended Vernakalant Brinavess May 4 2011 Following review we recommend reimbursement of vernakalant in the hospital setting Rotavirus Vaccine January 27 2010 Cost effectiveness analysis of a universal infant rotavirus vaccination programme in Ireland Agomelatine Valdoxan December 11 2009 Following a revision in price application we now consider agomelatine Valdoxan cost effective under the Community Drugs schemes Ustekinumab Stelara December 8 2009 We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish

    Original URL path: http://www.ncpe.ie/news/page/7/ (2015-10-30)
    Open archived version from archive

  • News | National Centre for Pharmacoeconomics - Part 8
    Assessment HTA of population based colectoral cancer screening programme in Ireland Sapropterin Kuvan June 18 2009 Sapropterin Kuvan is not a cost effective treatment for patients with phenylketonuria PKU Rivaroxaban Xarelto for the Primary Prevention of Venous Thromboembolic Events after Total Hip Knee Replacement September 18 2008 Reimbursement recommended Dabigatran Etexilate Pradaxa for the Primary Prevention of Venous Thromboembolic Events after Total Hip Knee Replacement September 11 2008 Reimbursement recommended Melatonin Circadin August 14 2008 We believe that there is currently insufficient evidence to support the reimbursement of this product under the Community Drugs Schemes Human Papillomavirus Vaccine July 29 2008 Health Technology Assessment on the role of vaccination against human papillomavirus in reducing the risk of cervical cancer in Ireland Nilotinib Tasigna CML resistant intolerant to imatinib February 29 2008 The cost effectiveness of nilotinib compared to dasatinib in patients resistant to imatinib has not been demonstrated Lapatinib Tyverb January 28 2008 Lapatinib could be considered cost effective inIreland However in view of the uncertainty surrounding the ICER we NCPE suggest conditional reimbursement under the High Tech Drugs scheme Sublingual Immunotherapy Grazax September 4 2007 The cost effectiveness of Grazax remains to be established and this product cannot be

    Original URL path: http://www.ncpe.ie/news/page/8/ (2015-10-30)
    Open archived version from archive

  • News | National Centre for Pharmacoeconomics - Part 9
    this Section About Us Current Staff News Glossary Contact Us Vacancies Pneumococcal conjugate vaccine March 8 2007 Cost effectiveness analysis of a universal infant pneumococcal conjugate vaccination programme in Ireland Sunitinib Sutent November 9 2006 The following report was prepared by the National Centre for Pharmacoeconomics and submitted on request to the Department of Health and Children Inhaled insulin Exubera July 13 2006 The following reports were prepared by the

    Original URL path: http://www.ncpe.ie/news/page/9/ (2015-10-30)
    Open archived version from archive

  • Glossary | National Centre for Pharmacoeconomics
    V W Absolute risk The probability of an event or outcome occurring in a defined population over a specified time period Absolute risk reduction A measure of treatment effect that compares the decrease in risk in the control group with that of a treatment group i e Pc Pt Adverse event An undesirable effect of a health technology Base Case Analysis conducted using the set of preferred methods most appropriate for the decision maker Bayesian Method A branch of statistics that uses prior information based on subjective opinion and objective evidence such as the results of previous research for estimation and inference Bias Bias is any distorting influence that makes the results of a study an inaccurate reflection of the true situation Blinding When patients investigators researchers and or assessors are kept unaware of the allocation of treatments investigational agent or control to participants in a study Budget Impact Analysis Estimates the financial consequences of adoption and diffusion of a new health care intervention within a specific health care setting or system context given inevitable resource constraints Clinical outcome An outcome of major clinical importance that is defined on the basis of the disease being studied e g fracture in

    Original URL path: http://www.ncpe.ie/category/glossary/ (2015-10-30)
    Open archived version from archive

  • B | National Centre for Pharmacoeconomics
    U V W Base Case Analysis conducted using the set of preferred methods most appropriate for the decision maker Bayesian Method A branch of statistics that uses prior information based on subjective opinion and objective evidence such as the results of previous research for estimation and inference Bias Bias is any distorting influence that makes the results of a study an inaccurate reflection of the true situation Blinding When patients

    Original URL path: http://www.ncpe.ie/category/glossary/b/ (2015-10-30)
    Open archived version from archive